Measles aerosol vaccination.
Measles ranks fifth among the five major childhood conditions which are responsible for 21% of all deaths in low and middle-income countries. Measles immunization is considered the most cost-effective public health intervention in the world. In recent years, there has been a critical need to identify alternative routes of measles immunization, which are rapid, reliable, cost-effective, needle-free, and suitable for use in mass campaigns. Aerosol administration of measles vaccines in mass campaigns was first proposed by Dr. Albert Sabin. We review the different clinical trials that have been conducted using the classic Mexican device as well as issues regarding vaccine strain, presentation, and manufacturer. Results of clinical trials indicate that the method is safe and immunogenic in infants and school age children. The viral inoculum will probably need to be increased when administered to infants. From the logistical point of view, the use of the aerosol method has not been evaluated in routine immunization although feasibility of its routine implementation was proved in mass campaigns in Mexico. Cost savings will probably be demonstrated. As to licensure, its compliance with the appropriate international regulatory requirements for medical aerosol delivery devices is in process.
Valdespino-Gómez
J L
JL
Coordination of the National Institutes of Health, Periférico Sur, Del Alvaro Obregón, Mexico. jvaldesp@insp.mx
de Lourdes Garcia-Garcia
M
M
Fernandez-de-Castro
J
J
Henao-Restrepo
A M
AM
Bennett
J
J
Sepulveda-Amor
J
J
D000280:Administration, Inhalation; D000336:Aerosols; D006801:Humans; D008457:Measles / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D008458:Measles Vaccine / Q000008:administration & dosage* / Q000276:immunology
D000336:Aerosols; D008458:Measles Vaccine